A world-class clinical research hub with global regulatory acceptance
Israel is one of the world's leading destinations for clinical research. With a highly educated population, cutting-edge medical infrastructure, world-renowned academic medical centres and a culture of innovation deeply embedded in its healthcare system, Israel consistently delivers high-quality clinical trial data that is accepted by global regulatory authorities.
aCROss Medical works with Israel's leading hospitals and specialist investigative sites, providing sponsors with access to top-tier principal investigators, experienced trial coordinators and a robust regulatory infrastructure. Our local presence ensures fast, efficient study start-up and ongoing operational excellence throughout the study lifecycle.
Clinical trials in Israel are overseen by the Ministry of Health (MOH) and Helsinki Committees at each investigative site. Israel has a well-established regulatory framework that fully aligns with ICH E6(R2) GCP standards. The Israeli MOH is a recognised and respected authority — data from Israeli sites is routinely accepted in global regulatory submissions, including US FDA and EMA applications.
Typical regulatory and ethics timelines in Israel are 3–5 months from submission to approval, reflecting the rigorous but well-structured review process.
Our Israeli sites have extensive experience in oncology, immunology, cardiology, neurology, dermatology, endocrinology, rare diseases and medical devices. Israel's position as a global leader in medical technology makes it a particularly strong destination for device and diagnostic trials.
aCROss Medical's Israel team includes experienced CRAs, regulatory affairs specialists and project managers who work directly with investigators and sponsor teams. We navigate the local regulatory and operational landscape on your behalf, delivering transparent communication and high-quality data throughout the study.